Top

Published in:

Open Access 01-12-2012 | Research

Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus Type-1 mono-infection and co-infection with hepatitis C Virus

Authors: Shimeru Kamihira, Tetsuya Usui, Tatsuki Ichikawa, Naoki Uno, Yoshitomo Morinaga, Sayaka Mori, Kazuhiro Nagai, Daisuke Sasaki, Hiroo Hasegawa, Katsunori Yanagihara, Takuya Honda, Yasuaki Yamada, Masako Iwanaga, Takashi Kanematu, Kazuhiko Nakao

Published in: Virology Journal | Issue 1/2012

Abstract

Background

Human T-cell leukemia virus type-1 (HTLV-1) carriers co-infected with and hepatitis C virus (HCV) have been known to be at higher risk of their related diseases than mono-infected individuals. The recent studies clarified that IL-28B polymorphism rs8099917 is associated with not only the HCV therapeutic response by IFN, but also innate immunity and antiviral activity. The aim of our research was to clarify study whether IL-28B gene polymorphism (rs8099917) is associated with HTLV-1/HCV co-infection.

Results

The genotyping and viral-serological analysis for 340 individuals showed that IL-28B genotype distribution of rs8099917 SNP did not differ significantly by respective viral infection status. However, the IL-28B mRNA expression level was 3.8 fold higher in HTLV-1 mono-infection than HTLV-1/HCV co-infection. The high expression level was associated with TT (OR, 6.25), whiles the low expression was associated with co-infection of the two viruses (OR, 9.5). However, there was no association between down-regulation and ATL development (OR, 0.8).

Conclusion

HTLV-1 mono-infection up-regulates the expression of IL-28B transcripts in genotype-dependent manner, whiles HTLV-1/HCV co-infection down-regulates regardless of ATL development.

Available only for authorised users

Kamihira S, Yamada Y, Sohda H, Atogami S, Tomonaga M, Egawa S, Fujii M, Chifu K: Human T-lymphotropic virus type-I influence on hepatotropic virus infections and the subsequent development of hepatocellular carcinoma. Cancer Detect Prev 1994,18(5):329-334.PubMed

Takeoka H, Furusyo N, Toyoda K, Murata M, Sagara Y, Kashiwagi S, Hayashi J: Antibody to the human T-lymphotropic virus type 1 (HTLV-1) envelope protein Gp46 in patients co-infected with HCV and HTLV-1. Am J Trop Med Hyg 2007,77(1):192-196.PubMed

Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, Mueller N: A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000,181(1):35-41. 10.1086/315177PubMedCrossRef

Kohno T, Yamada Y, Akamatsu N, Kamihira S, Imaizumi Y, Tomonaga M, Matsuyama T: Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005,6(8):527-33.CrossRef

Kishihara Y, Furusyo N, Kashiwagi K, Mitsutake A, Kashiwagi S, Hayashi J: Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis 2001,184(9):1114-1119. 10.1086/323890PubMedCrossRef

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009,461(7262):399-401. 10.1038/nature08309PubMedCrossRef

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009,41(10):1105-1109. 10.1038/ng.449PubMedCrossRef

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003,4(1):69-77.PubMedCrossRef

Li M, Liu X, Zhou Y, Su SB: Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009,86(1):23-32. 10.1189/jlb.1208761PubMedCrossRef

10.

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009,461(7265):798-801. 10.1038/nature08463PubMedPubMedCentralCrossRef

11.

Kamihira S, Terada C, Sasaki D, Yanagihara K, Tsukasaki K, Hasegawa H, Yamada Y: Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations. Eur J Haematol 2009,82(4):301-307. 10.1111/j.1600-0609.2009.01211.xPubMedCrossRef

12.

Usui T, Yanagihara K, Tsukasaki K, Murata K, Hasegawa H, Yamada Y, Kamihira S: Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells. Retrovirology 2008,22(5):34.CrossRef

13.

Baloopa S, Thomas DavidL, Thio ChloeL: IL-28B and the control of HCV infection. Gastroenterology 2010,139(6):1865-1875. 10.1053/j.gastro.2010.10.004CrossRef

14.

Maureen PM, Ying Q, James J G, Shehnaz KH, regoly DK, Keith HW, Susan B: IL-28B polymorphism does not determine outcomes of HBV or HIV infection. 2010,202(11):1749-1753.

15.

Birmann BM, Breen EC, Stuver S, Cranston B, Martínez-Maza O, Falk KI, Okayama A, Hanchard B, Mueller N, Hisada M: Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica. Int J Cancer 2009,124(3):614-21. 10.1002/ijc.24012PubMedPubMedCentralCrossRef

16.

Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J: German Anti-D Study Group.: A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010,139(5):1586-92. 1592.e1 10.1053/j.gastro.2010.07.005PubMedCrossRef

17.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009,41(10):1100-1104. 10.1038/ng.447PubMedCrossRef

18.

Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR: Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006,80(9):4501-4509. 10.1128/JVI.80.9.4501-4509.2006PubMedPubMedCentralCrossRef

19.

Osterlund P, Veckman V, Sirén J, Klucher KM, Hiscott J, Matikainen S, Julkunen I: Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005,79(15):9608-9617. 10.1128/JVI.79.15.9608-9617.2005PubMedPubMedCentralCrossRef

20.

Diegelmann J, Beigel F, Zitzmann K, Kaul A, Göke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S: Comparative Analysis of the Lambda-Interferons IL-28A and IL-29 regarding Their Transcriptome and Their Antiviral Properties against Hepatitis C Virus. PLoS One 2010,5(12):e15200. 10.1371/journal.pone.0015200PubMedPubMedCentralCrossRef

21.

Mennechet FJD, Uze D: FN-λ-treated dendritic cells specifically induce proliferation of Foxp3-expressing suppressor T-cells. Blood 2006, 107: 4417-4423. 10.1182/blood-2005-10-4129PubMedCrossRef

Title: Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus Type-1 mono-infection and co-infection with hepatitis C Virus
Authors: Shimeru Kamihira
Tetsuya Usui
Tatsuki Ichikawa
Naoki Uno
Yoshitomo Morinaga
Sayaka Mori
Kazuhiro Nagai
Daisuke Sasaki
Hiroo Hasegawa
Katsunori Yanagihara
Takuya Honda
Yasuaki Yamada
Masako Iwanaga
Takashi Kanematu
Kazuhiko Nakao
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-9-40

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Erratum to: Hepatitis B virus infection and replication in human bone marrow mesenchymal stem cells

The soluble amino-terminal region of HVEM mediates efficient herpes simplex virus type 1 infection of gD receptor-negative cells

Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of anti-CMV IgG in Chinese children

A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon

High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study

Bioinformatics and evolutionary insight on the spike glycoprotein gene of QX-like and Massachusetts strains of infectious bronchitis virus

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials